Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

Official Title

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Summary:

The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.

Trial Description

Primary Outcome:

• Progression-free Survival

• Overall Survival
• Overall Response
• Duration of Response
• Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy
• Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)
• Change From Baseline in Right Ventricular Fractional Area Change (FAC)
• Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)

View this trial on ClinicalTrials.gov